AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures LLC (“DPV”) today announced the successful completion of the previously announced tender offer for Lumos Pharma’s shares at a purchase price of (i) $4.25 per share in cash at... Read More

AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the 62nd Annual European Society... Read More

AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company’s Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting , or ESPE 2024, to be held... Read More

AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that the Company has entered into a definitive merger agreement, dated October 22, 2024 (the “Merger Agreement”) whereby Double Point Ventures LLC (“DPV”) will acquire 100% of Lumos Pharma’s outstanding shares... Read More

AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society , or APPES 2024, to be held October 2-5,... Read More

AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials has been accepted for presentation at the XXXI Meeting of the Latin American Society of Paediatric Endocrinology (Sociedad Latinoamericana de... Read More

AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9 th – 11 th in New York City. Lumos Pharma management will be present to host one-on-one meetings on Monday and Tuesday,... Read More

Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to Initiate Phase 3 Trial in Q2 2025 Company to Host Conference Call Today at 4:30PM ET AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics... Read More

AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024 financial results after the market close on Thursday, August 1, 2024. The company will host a conference call and webcast at 4:30pm ET that day to discuss these financial results and provide an update on clinical and... Read More

AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO) , held in Boston, MA, June 1-4, 2024. The posters were presented in parallel... Read More

AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO) , to be held in Boston, MA June 1-4, 2024.... Read More

Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months Company to Host Conference Call May 15, 2024, at 8:30AM ET AUSTIN, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical... Read More

AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial results before market open on Wednesday, May 15, 2024. The company will host a conference call and webcast at 8:30 AM ET that day to discuss these financial results and provide an update on clinical and... Read More

AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe. Pediatric Endocrine... Read More

AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that on Thursday, March 14, 2024, the Company received a Notice of Allowance from the US Patent and Trade Office (USPTO) for claims in its patent application number PCT/US22/050700... Read More

End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Moderate PGHD Met All Primary and Secondary Endpoints Pisit “Duke” Pitukcheewanont, MD, Appointed Chief Medical Officer Conference Call Today at 4:30 PM EST AUSTIN, Texas, March 07, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.... Read More

AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market close on Thursday, March 7, 2024. The company will host a conference call and webcast at 4:30 PM ET that day to discuss... Read More

AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will participate in the Oppenheimer 34 th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024. Lumos Pharma’s management will present and host virtual... Read More

AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc . (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukcheewanont, MD, known also as Dr. Duke, to the position of Chief Medical Officer (CMO), effective January 1, 2024. In this role, Dr. Pitukcheewanont will provide his leadership in Lumos Pharma's efforts to hone its clinical and... Read More

AUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail. Management will be joined by three... Read More

AUSTIN, Texas, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the Company will participate in the Piper Sandler 35 th Annual Healthcare Conference being held November 28 th – 30 th in New York City. Lumos Pharma management will present and host one-on-one meetings at the conference. Piper Sandler... Read More

Phase 2 Data for Potentially the First Oral Therapeutic for PGHD Met All Primary and Secondary Endpoints with Supportive Evidence to Advance to Phase 3 OraGrowtH210 Trial Results Show LUM-201 Dose of 1.6 mg/kg Achieves AHVs of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Consistent with Historical Growth Rates for Moderate PGHD Population OraGrowtH212 Data Confirm Unique Pulsatile Mechanism of Action of LUM-201and... Read More

OraGrowtH210 Results Show LUM-201 Dose of 1.6 mg/kg Achieves Annualized Height Velocities (AHV) of 8.2 cm/yr at 6 Months and 8.0 cm/yr at 12 Months, Comparable to Growth Rates for Moderate PGHD Population Delta at 6 and 12-month AHV Between Optimal LUM-201 Dose of 1.6 mg/kg and rhGH Comparator Arm is Within the Non-inferiority... Read More

Deconvolution Analysis Shows 60% Increase in GH Secretion, Comparable to Established Values in Normal Children Analysis Shows Annualized Height Velocity Increased ~62% Compared to Baseline Data Support LUM-201 Mechanism of Action in Moderate PGHD Patient Population AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for... Read More

AUSTIN, Texas, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that an abstract reviewing interim data from its OraGrowtH212 Trial has been accepted for oral presentation at the 2023 annual meeting of the European Society for... Read More

AUSTIN, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11 th – 13 th and the Cantor Global Healthcare Conference... Read More

AUSTIN, Texas, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that an independent, key opinion leader (KOL) panel of five pediatric endocrinologists will participate in a webinar for discussion of PGHD, the current injectable... Read More

Confirms Timing for Primary Outcome Data Readout for two Phase 2 OraGrowtH Trials in Q4 2023 Late Breaking Abstract Accepted for Oral Presentation at ESPE 2023 Encouraging Interim Data from OraGrowtH Trials Presented at ENDO 2023, Highlighted in KOL Webinar Conference Call Scheduled for Today at 4:30pm ET AUSTIN, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc . (NASDAQ:LUMO), a biopharmaceutical company advancing... Read More

AUSTIN, Texas, July 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its second quarter 2023 financial results after market close on Wednesday, August 9, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to... Read More

AUSTIN, Texas, July 12, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company’s President & Chief Scientific Officer, John McKew, PhD, will participate in the Oppenheimer 2023 Life Sciences Summit to be held July 18 th – 20 t h in Montauk, NY,... Read More

AUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that Chief Medical Officer (CMO) Dr. David B. Karpf is departing the company to pursue other opportunities, effective June 29 th . Dr. Pisit “Duke” Pitukcheewanont,... Read More

Webinar to Review Data Demonstrating Potential Drug Effect and Durable Response Webinar to be held Today June 21, 2023 at 11:00 AM Eastern Time AUSTIN, Texas, June 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, is hosting today a virtual Key Opinion... Read More

AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 2023 BIO International Convention held June 5-8, 2023 in Boston and the Jefferies Healthcare Conference held June 7-9, 2023 in New York City. Lumos... Read More

AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that interim data from its OraGrowtH210 and OraGrowtH212 Trials will be reviewed in two oral presentations in Session OR21 – “Update on Growth Disorders” at the 2023... Read More

AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that management will participate in panel discussions at the World Orphan Drug Congress USA 2023 , held in Washington, D.C., May 23-25, 2023. John McKew, PhD, the... Read More

Oral and Poster Presentations on OraGrowtH Trials at PES 2023 Further Support Potential for LUM-201 as First Oral Treatment for Moderate Idiopathic PGHD OraGrowtH212 Interim Data Demonstrate LUM-201 Amplifies Natural Pulsatile GH-Secretion and that IGF-1 SDS and Serum Concentrations Remain within Normal Range AUSTIN, Texas, May 08, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company... Read More

Patient Enrollment Completed in both Phase 2 OraGrowtH Trials Primary Outcome Data for both OraGrowtH Trials Expected 4Q 2023 Interim Data from OraGrowtH Trials Accepted for Presentation at PES 2023 Conference Call Scheduled for Today at 4:30pm ET AUSTIN, Texas, May 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc . (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone... Read More

Oral Presentation on Growth Response to LUM-201 Treatment from OraGrowtH210 Trial Interim Data from OraGrowtH212 Trial Highlighted in Poster Presentation AUSTIN, Texas, April 27, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for idiopathic Pediatric Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials, announced today that interim... Read More

AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its first quarter 2023 financial results after market close on Wednesday, May 3, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to... Read More

AUSTIN, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in Oppenheimer’s 33 rd Annual Healthcare Conference held virtually March 13-15, 2023. Lumos Pharma will present and host virtual one-on-one meetings... Read More

Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis Baseline Characteristics of OraGrowtH210 Trial Subjects Highlighted in Poster Presentation AUSTIN, Texas, March 05, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through... Read More

Patient Enrollment Completed in OraGrowtH210 and OraGrowtH212 Trials Primary Outcome Data for both OraGrowtH Trials Expected Q4 2023 Additional Data from OraGrowtH Trials to be Presented at IMPE 2023 Conference Call Scheduled for Today at 4:30 ET AUSTIN, Texas, March 01, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today... Read More

Phase 2 OraGrowtH210 and Phase 2 PK/PD OraGrowtH212 Trials Are Fully Enrolled Primary Outcome Data for Both OraGrowtH Trials Expected 4Q 2023 AUSTIN, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that the last subjects have been... Read More

AUSTIN, Texas, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2022 financial results after market close on Wednesday, March 1, 2023. The company will host a conference call and webcast at 4:30 PM ET that day to discuss... Read More

AUSTIN, Texas, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the 12 th Annual LifeSci Partners Corporate Access... Read More

AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the field of pediatric endocrinology on December 6 th to review the Company’s interim data from two Phase 2 trials evaluating oral LUM-201 in moderate idiopathic Pediatric Growth Hormone Deficiency (iPGHD). Andrew Dauber, MD, MMSc,... Read More